



Hämorrhagische Diathesen – Teil 2: „Gerinnung praktisch“ an den Beispielen disseminierte intravasale Gerinnung (DIC) und erworbene Hemmkörper-Hämophilie

- 1) Taylor FB, Toh C-H, Hoots WK, Wada H, Levi M, on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. *Thromb Haemost* 2001; 86:1327-30.
- 2) Levi M. Current understanding of disseminated intravascular coagulation. *Brit J Haematol* 2004; 124:567-576.
- 3) Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. *Haemostasis* 1999; 29:111-134.
- 4) Ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. *Thromb Haemost* 1999; 82:713-717.
- 5) Slofstra SH, Spek A, ten Cate H. Disseminated intravascular coagulation. *The Hematology Journal* 2003; 4:295-302.
- 6) Levi M, ten Cate H. Disseminated intravascular coagulation. *N Engl J Med* 1999; 341:586-592.
- 7) Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. *Thromb Haemost* 1999; 82:695-705.
- 8) Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. *J Thromb Haemostas* 2003;1:1897-1905.
- 9) Esmon CT. Inflammation and thrombosis. *J Thromb Haemostas* 2003; 1:1343-1348.
- 10) Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. *Thromb Res* 2002; 107:S9-S17.
- 11) Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. *Sem Thromb Hemost* 2001; 27:569-75.
- 12) Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut, J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, for the PROWESS Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344:699-709.
- 13) Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; 348:138-150.
- 14) Hoots WK. Non-overt disseminated intravascular coagulation: definition and pathophysiological implications. *Blood Rev* 2002; 16:S3-S9.
- 15) Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. *Thromb Haemost* 1999; 82:718-721.
- 16) Müller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. *Thromb Haemost* 1999; 82:706-712.
- 17) Seifried E, Mueller M. Disseminierte intravasale Gerinnung. In: *Leukämitherapie - 2. Auflage*. Hoelzer D, Seipelt G (eds.). UNI-MED (Bremen) 2004; 9:130-142.
- 18) Bouchard BA, Tracy PB. The participation of leukocytes in coagulant reactions. *J Thromb Haemostas* 2003; 1:464-469.





- 19) Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Péntzes I, Kübler A, Knaub S, Keinecke H-O, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, for the KyberSept Trial Study Group. High-Dose Antithrombin III in Severe Sepsis. – A Randomized Controlled Trial. *JAMA* 2001; 286:1869-1878.
- 20) von Depka Prondzinski M. Hämostasestörungen bei onkologischen Patienten. *Internist* 2005; 46:48-56.
- 21) Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. *Ann Med* 2004; 36:41-49.
- 22) Wada H. Disseminated intravascular coagulation. *Clin Chim Acta* 2004; 344:13-21.
- 23) Norman KE. Alternative Treatments for Disseminated Intravascular Coagulation. *Drug News Perspect* 2004; 17:243-250.
- 24) Franchini M, Manzato F. Update on the Treatment of Disseminated Intravascular Coagulation. *Hematology* 2004; 9:81-85.
- 25) ten Cate H. Thrombocytopenia: One of the Markers of Disseminated Intravascular Coagulation. *Pathophysiol Haemost Thromb* 2003/2004; 33:413-416.
- 26) Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. *BMJ* 2004; 329:480-488.
- 27) Matsuda t et al. Clinical aspects of DIC- disseminated intravasal coagulation. *Pol J Pharmacol* 1996; 48:73-5
- 28) Mueller MM, Seifried E: Disseminierte intravasale Gerinnung (DIC). In: Rationelle Therapie mit Blutkomponenten und Plasmaderivaten – 2. Auflage. Hellstern P, Seyfert UT (eds.). UNI-MED (BREMEN) 2005; 9.3:203-219
- 29) Franchini M et al. Acquired hemophilia A. A concise review. *Am J Hematol* 2005; 80:55
- 30) Green D et al. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. *Thromb Haemost* 1982; 45:200
- 31) Delago J. Acquired Hemophilia: Review and metaanalysis focused on therapy and prognostic factors. *BJH* 2003; 121:21-35
- 32) Collins P et al. A population based, unselected, consecutive cohort of patients with acquired hemophilia. *Br J Haematol* 2004;124:86
- 33) Hauser I et al. Solid tumors and factor VIII antibodies. *Thromb Haemost* 1999; 82:1005
- 34) Greed D et al. Factor VIII antibodies in rheumatoid arthritis. Effect of cyclophosphamide. *Arch Intern Med* 1980; 140:1232
- 35) Hauser I et al. Post partum Factor VIII inhibitors. A review of the literature with special reference to the value of steroid an immunosuppressive treatment. *Thromb Haemost* 1995; 73:1
- 36) Liebmann HA et al. Activated recombinant human coagulation factor VII therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. *Am J Haematol* 2000; 63:109
- 37) Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM; KyberSept investigators. Benefit risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. *Thromb Haemost.* 2006; 95:850-856.